1,641
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Economic burden associated with adverse events of special interest in patients with relapsed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in the United States

, , , &
Pages 573-580 | Received 16 May 2018, Accepted 15 Jun 2018, Published online: 02 Jul 2018

Figures & data

Figure 1. Patient selection flowchart for adults with relapsed Ph− B-cell ALL.

Ph−: philadelphia chromosome-negative; ALL: acute lymphoblastic leukemia; ICD: International Classification of Diseases; DRG: diagnosis related group; Ph+: Philadelphia chromosome-positive.

Figure 1. Patient selection flowchart for adults with relapsed Ph− B-cell ALL.Ph−: philadelphia chromosome-negative; ALL: acute lymphoblastic leukemia; ICD: International Classification of Diseases; DRG: diagnosis related group; Ph+: Philadelphia chromosome-positive.

Figure 2. Study period schema.

Figure 2. Study period schema.

Table 1. Baseline characteristics of adult relapsed Ph− B-cell ALL patients with AESI.

Figure 3. AESI frequency by event type.

*AESI: adverse events of special interest; GI: gastrointestinal.

Figure 3. AESI frequency by event type.*AESI: adverse events of special interest; GI: gastrointestinal.

Table 2. Total, inpatient, and outpatient costs of AESI by event type during follow-up.

Table 3. Plan-paid inpatient and outpatient costs of AESI by event type during follow-up.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.